no NSAID
Phase 3Small molecule
no NSAID is one of 50 small molecule programs targeting Chronic pain. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
49
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
77 competitors in Chronic Pain
#DrugCompanyPhaseTrials
1Ketalar
AAultman Health Foundation
Approved
Elavil
AstraZenecaApproved
Marinol
Jazz PharmaceuticalsApproved
Dolophine
HHikma Pharmaceuticals LLC
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Tylenol
KKenvue Brands
Approved
Marcaine
IInnocoll
Approved
Decadron
AAspen Global Incorporated
Approved
Adrenaline
SSamson Clinical Operations Pty Ltd
Approved
Minocin
TTriax
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for no NSAID. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details